

## ASX Announcement

15 May 2023

### HALF YEAR INTERIM DIVIDEND ANNOUNCEMENT

EZZ Life Science Holdings Limited (**ASX: EZZ**, or the **Company**), is pleased to announce that after due consideration, the Board has determined the following fully franked interim dividend to shareholders for the half year ending 31 December 2022.

#### Dividend Timetable

Dividend amount:	\$0.0098 per share fully franked
Ex-dividend date:	22 May 2023
Record date:	23 May 2023
Payment date:	23 June 2023

You must be registered as a holder of securities of EZZ on the Record date to be eligible for this dividend. To ensure prompt dividend payments please ensure that the correct bank details have been provided to the registry, Boardroom Pty Limited, prior to the Record date.

*This announcement has been authorised by the Board of EZZ Life Science Holdings Limited.*

-ENDS-

#### For further information, please contact:

James Hudson  
Corporate Affairs for EZZ Life Science Holdings Limited  
P 0467 761 166  
E [james.hudson@ezzlife.com.au](mailto:james.hudson@ezzlife.com.au)

#### About EZZ Life Science Holdings Limited

[EZZ Life Science Holdings Limited \(ASX:EZZ\)](#) is an Australian genomic life science company with a mission to improve quality of life and human health. EZZ Life Science has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. EZZ Life Science is passionate about investing in the future of consumer health through the development of e-commerce and distribution of high-quality products via omnichannel models across Australia, New Zealand, China and worldwide. EZZ Life Science is led by an experienced senior management team that have implemented strategies to drive rapid and ongoing growth of the business.

For more information, please visit our corporate site [ezzlife.com.au](http://ezzlife.com.au) and our consumer site [ezzdna.com.au](http://ezzdna.com.au).